Global (Re)Insurance Experts Convened at BILTIR’s Largest Ever Bermuda International Life & Annuity Conference
22.9.2025 14:00:00 CEST | Business Wire | Press Release
Bermuda International Long Term Insurers and Reinsurers (BILTIR), a trade association comprised of more than 70 (re)insurance companies and service providers in Bermuda, concluded its 13th annual Bermuda International Life and Annuity Conference at the Hamilton Princess Hotel and Beach Club last week.
The only conference solely focused on the long-term (re)insurance industry in Bermuda, this year had a record-breaking 500+ global industry professionals in attendance, with representation from 17 countries and 49% of the delegation traveling internationally. It was also the inaugural year in which the conference expanded to two days of speeches, panels, and networking events focusing on the resilience and deep purpose of the jurisdiction within the broader (re)insurance landscape.
“Bermuda’s long-term sector continues to expand on the strength of our leading regulatory framework. This strong regulation attracts quality companies that are helping to solve global pension gap challenges,” said Bermuda’s Premier, the Hon. E. David Burt, JP, MP. “Our focus is on growth that benefits both our economy and our people, supported by international partnerships. I thank BILTIR for their commitment; together, we will ensure that Bermuda remains the best jurisdiction to operate in for a long-term insurer.”
The BMA reports that Bermuda long-term commercial (re)insurers incurred US$549 billion in gross claims costs to policyholders and cedants globally during the nine-year period from 2016 to 2024 – highlighting the industry’s strength and reliability, underpinned by the BMA’s commitment to maintain its regulatory strength.
“The growing demand for insights and networking at our conference confirms Bermuda’s role at the center of the global (re)insurance sector,” said Natasha Scotland Courcy, chair of BILTIR’s Board of Directors and CEO and General Counsel at Athene Life Re. “Through discussions on innovative strategies, risk management, and collaboration to strengthen policyholder protections, attendees walked away with both practical insights and renewed energy.”
BILTIR was joined by many distinguished authorities in their fields, including Utah Insurance Commissioner and NAIC Secretary and Treasurer Jon Pike; Deputy Managing Director of Supervision at the Bermuda Monetary Authority Gerald Gakundi; Head of Prudential Regulation & International Affairs/Reinsurance at Insurance Europe Angus Scorgie (virtually); and many more. Additionally, BILTIR welcomed visionary technologist Maurice Conti, who shared a keynote address about harnessing AI to redefine the life insurance industry.
Sessions dove deep into the topics of the long term insurance’s impact on Bermuda’s economic growth, the continued confidence in Bermuda’s ability to guide the industry in the future, reinsurance’s crucial role in stabilizing global risk, the growing importance of private credit in the (re)insurance landscape, and how reinsurers are helping to strengthen the financial foundations of retirement and insurance guarantees.
Coinciding with the conference, the Bermuda Monetary Authority (BMA) released its latest stress test, which evaluated Bermuda’s long-term insurance sector’s ability to withstand severe market shocks and tied back to the themes woven throughout the Bermuda International Life and Annuity Conference. The results found that Bermudian (re)insurers maintain adequate capital to withstand financial stresses and manage risk appropriately – showing overwhelming resilience to potential market challenges and fluctuations.
For more information about BILTIR, please visit its website. To stay up to date on the 2026 Bermuda International Life and Annuity Conference, follow BILTIR’s LinkedIn page.
About BILTIR
Bermuda International Long Term Insurers and Reinsurers (BILTIR) represents the long-term insurers and reinsurers in Bermuda. Backed by Bermuda's over 40-year history of providing insurance solutions and at the forefront of the evolving long-term insurance industry, BILTIR represents the policy interests and drives advocacy for the market and its members. BILTIR membership is comprised of more than 70 annuity, life insurance and reinsurance businesses and servicing companies on the island. To learn more, visit https://www.biltir.bm/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250922817317/en/
Contacts
Emma Zubiago
401-226-7886
ezubiago@prosek.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom